Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272219 · ClinicalTrials.gov registry record · Phase 3
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
A Phase 3 study of Obesity and Metabolism and Nutrition Disorder, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,731
- Enrollment target
- 20
- Study locations
NCT01272219 is a Phase 3 study of Obesity and Metabolism and Nutrition Disorder that has completed, run by Novo Nordisk A/S. The registered enrollment target is 3,731 participants, above the 815-participant average among 1,053 other Obesity trials with a reported enrollment target (358% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT01272219, a Phase 3 study of Obesity and Metabolism and Nutrition Disorder, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,731 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline. Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).
Conditions Studied
Interventions
- DRUG placebo
- DRUG liraglutide
Study Locations (20)
California
- Novo Nordisk Investigational Site - Anaheim
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Huntington Beach
- Novo Nordisk Investigational Site - La Jolla
- Novo Nordisk Investigational Site - San Diego
- Novo Nordisk Investigational Site - San Diego
- Novo Nordisk Investigational Site - Santa Monica
Florida
- Novo Nordisk Investigational Site - Boynton Beach
- Novo Nordisk Investigational Site - Bradenton
- Novo Nordisk Investigational Site - Crystal River
- Novo Nordisk Investigational Site - Daytona Beach
- Novo Nordisk Investigational Site - Jacksonville
Colorado
- Novo Nordisk Investigational Site - Aurora
- Novo Nordisk Investigational Site - Colorado Springs
- Novo Nordisk Investigational Site - Golden
Connecticut
- Novo Nordisk Investigational Site - New London
- Novo Nordisk Investigational Site - Waterbury
Alabama
- Novo Nordisk Investigational Site - Birmingham
Arizona
- Novo Nordisk Investigational Site - Phoenix
District of Columbia
- Novo Nordisk Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,731 participants |
| Start Date | 2011-06-01 |
| Est. Completion | 2015-03-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01272219
The ClinicalTrials.gov registry entry for NCT01272219 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,731 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 815-participant average among 1,053 other Obesity trials with a reported enrollment target (358% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01272219 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01272219 about?
NCT01272219 is a clinical study titled "Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes". This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim i...
What is the current status of trial NCT01272219?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,731 participants. The study started on 2011-06-01. Estimated completion is 2015-03-02.
What conditions does trial NCT01272219 study?
This clinical trial studies the following conditions: Obesity, Metabolism and Nutrition Disorder.
What interventions are being tested in trial NCT01272219?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT01272219?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01272219 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.